Methods
A review of a prospectively collected database of all paediatric liver disease (age less than 18 years) managed for LCH at our unit between January 2014 and December 2020 was performed. Each patient would be discussed in multidisciplinary meet consisting of paediatric hepatologist and paediatric oncologist, prior to initiation of therapy. These patients would be jointly managed by both the teams until completion of treatment. Eight patients were identified with a diagnosis of LCH and hepatic involvement, of whom six subsequently underwent LT. Data with regards to their baseline demography, age of presentation of LCH and diagnosis, type of hepatic involvement, Pediatric end stage liver disease (PELD)score, sites of extrahepatic involvement, modality of diagnosis, chemotherapy protocols, disease remission and survival were analysed. In patients who underwent LT, interval from diagnosis of LCH to LT, the type of LT (living donor or deceased donor), type of liver graft, intra operative or post-operative complications, duration of hospital stay, post LT chemotherapy regimen, immunosuppression protocol and long term survival were analysed. Institute ethical board approval was obtained for performing the current analysis.